| 2017-2-C | Drugs and the Elderly 2017-2-C | Miscellaneous |
| 2013-1 | Drugs and the Elderly 2013-1 | Miscellaneous |
| 2009-1 | Drugs and the Elderly 2009-1 | Miscellaneous |
| 2006-2 | Drugs and the Elderly 2006-2 | Miscellaneous |
| 2004-2 | Drugs and the Elderly 2004-2 | Miscellaneous |
| 2009-1 | Drugs in Children 2009-1 | Miscellaneous |
| 2009-1 | Drugs in Pregnancy 2009-1 | Miscellaneous |
| 2010-1 | Variations in Drug levels 2010-1 | Miscellaneous |
| 2005-1 | Variations in Drug Response 2005-1 | Miscellaneous |
| 2012-1 | Agonists 2012-1 | Pharmacodynamics |
| 2011-2 | Agonists 2011-2 | Pharmacodynamics |
| 2013-2-D | Antagonists 2013-2-D | Pharmacodynamics |
| 2011-2 | Antagonists 2011-2 | Pharmacodynamics |
| 2010-1 | Antagonists 2010-1 | Pharmacodynamics |
| 2008-1 | Antagonists 2008-1 | Pharmacodynamics |
| 2003-2 | Antagonists 2003-2 | Pharmacodynamics |
| 2017-1-A | Efficacy and Potency 2017-1-A | Pharmacodynamics |
| 2013-1 | Efficacy and Potency 2013-1 | Pharmacodynamics |
| 2010-2 | Efficacy and Potency 2010-2 | Pharmacodynamics |
| 2008-2 | Efficacy and Potency 2008-2 | Pharmacodynamics |
| 2007-1 | Efficacy and Potency 2007-1 | Pharmacodynamics |
| 2006-1 | Efficacy and Potency 2006-1 | Pharmacodynamics |
| 2005-1 | Efficacy and Potency 2005-1 | Pharmacodynamics |
| 2010-1 | Second Messengers 2010-1 | Pharmacodynamics |
| 2008-1 | Second Messengers 2008-1 | Pharmacodynamics |
| 2006-2 | Second Messengers 2006-2 | Pharmacodynamics |
| 2004-2 | Second Messengers 2004-2 | Pharmacodynamics |
| 2003-2 | Second Messengers 2003-2 | Pharmacodynamics |
| 2012-2 | Signalling Mechanisms 2012-2 | Pharmacodynamics |
| 2010-1 | Spare Receptors 2010-1 | Pharmacodynamics |
| 2009-2 | Spare Receptors 2009-2 | Pharmacodynamics |
| 2006-2 | Spare Receptors 2006-2 | Pharmacodynamics |
| 2011-1 | Absorption 2011-1 | Pharmacokinetics |
| 2005-2 | Absorption 2005-2 | Pharmacokinetics |
| 2014-1-D | Bioavailability 2014-1-D | Pharmacokinetics |
| 2013-1 | Bioavailability 2013-1 | Pharmacokinetics |
| 2011-2 | Bioavailability 2011-2 | Pharmacokinetics |
| 2008-1 | Bioavailability 2008-1 | Pharmacokinetics |
| 2005-1 | Bioavailability 2005-1 | Pharmacokinetics |
| 2003-2 | Bioavailability 2003-2 | Pharmacokinetics |
| 2014-2-D | Biotransformation 2014-2-D | Pharmacokinetics |
| 2012-2 | Biotransformation 2012-2 | Pharmacokinetics |
| 2012-1 | Biotransformation 2012-1 | Pharmacokinetics |
| 2011-1 | Biotransformation 2011-1 | Pharmacokinetics |
| 2009-2 | Biotransformation 2009-2 | Pharmacokinetics |
| 2005-2 | Biotransformation 2005-2 | Pharmacokinetics |
| 2003-1 | Biotransformation 2003-1 | Pharmacokinetics |
| 2017-2-C | Clearance 2017-2-C | Pharmacokinetics |
| 2014-1-D | Clearance 2014-1-D | Pharmacokinetics |
| 2012-2 | Clearance 2012-2 | Pharmacokinetics |
| 2010-2 | Clearance 2010-2 | Pharmacokinetics |
| 2009-2 | Clearance 2009-2 | Pharmacokinetics |
| 2005-2 | Clearance 2005-2 | Pharmacokinetics |
| 2008-2 | CYP 450 2008-2 | Pharmacokinetics |
| 2007-2 | CYP 450 2007-2 | Pharmacokinetics |
| 2013-2-D | Elimination 2013-2-D | Pharmacokinetics |
| 2012-1 | Elimination 2012-1 | Pharmacokinetics |
| 2009-1 | Elimination 2009-1 | Pharmacokinetics |
| 2006-1 | Elimination 2006-1 | Pharmacokinetics |
| 2010-2 | First Pass Effect 2010-2 | Pharmacokinetics |
| 2008-2 | First Pass Effect 2008-2 | Pharmacokinetics |
| 2007-2 | First Pass Effect 2007-2 | Pharmacokinetics |
| 2009-1 | Half life 2009-1 | Pharmacokinetics |
| 2006-2 | Half life 2006-2 | Pharmacokinetics |
| 2007-1 | Phase 1 and Phase 1 Reactions 2007-1 | Pharmacokinetics |
| 2007-2 | Routes of Administration 2007-2 | Pharmacokinetics |
| 2012-2 | Volume of Distribution 2012-2 | Pharmacokinetics |
| 2011-1 | Volume of Distribution 2011-1 | Pharmacokinetics |
| 2009-1 | Volume of Distribution 2009-1 | Pharmacokinetics |
| 2007-1 | Volume of Distribution 2007-1 | Pharmacokinetics |
| 2006-1 | Volume of Distribution 2006-1 | Pharmacokinetics |
| 2003-1 | Volume of Distribution 2003-1 | Pharmacokinetics |
| | |
